Maxiflor

Quick links to important sections

Maxiflor

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxiflor

Quick Facts

Property Description
Active ingredient Diflorasone diacetate
Form Topical cream and ointment
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Relief of inflammatory skin symptoms
Origin Synthetic (fluorinated steroid)

What Type of Medication is Maxiflor?

Maxiflor is a synthetic, single-ingredient prescription medication designed for application directly to the skin, which belongs to the class of highly potent topical Corticosteroids. Its core component is Diflorasone diacetate, a fluorinated steroid derivative identified as a Glucocorticoid on the MeSH pharmacological classification. Unlike many common hydrocortisone preparations, Diflorasone diacetate is clinically recognized for its significantly higher potency, distinguishing it as a powerful therapeutic tool for severe inflammation. Glucocorticoids are a group of corticosteroids recognized for their pronounced anti-inflammatory activity.

Available Forms and Core Composition

The medication is compounded for topical application and is supplied as either a topical cream or a topical ointment, both containing 0.05% Diflorasone diacetate. The difference in the formulation base is essential: the cream typically uses an emollient base, while the ointment is compounded with a more occlusive hydrocarbon base. This formulation choice is a key differentiator, as the occlusive nature of the ointment base contributes to its classification as a very high potency agent, distinguishing it from the high-potency cream and allowing targeted use based on lesion characteristics.

What is the General Purpose of Maxiflor?

The general purpose of Maxiflor is to provide rapid and effective anti-inflammatory and antipruritic relief for inflammatory skin conditions. Topical corticosteroids, including this medication, are generally indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This means the medication works to quickly calm the excessive swelling, suppress the redness, and diminish the intense itching associated with inflammatory skin responses, offering potent symptomatic management often required for persistent skin flare-ups.

What side effects are possible with Maxiflor?

Adverse reaction scope

Maxiflor (diflorasone topical) is a very high-potency corticosteroid. Its safety profile primarily involves local dermatologic reactions and potential for systemic effects due to absorption.

  • Key adverse reaction categories: Skin and Subcutaneous Tissue Disorders, and Endocrine/Metabolic disorders.
  • System-organ classes involved: Skin, Endocrine, and Ophthalmic systems.
  • Frequency classification: The incidence of most reactions is generally reported as "Incidence not known" or "Uncommon" in official documentation, though local reactions are the most frequently observed.
  • Serious adverse reactions (as documented in regulatory sources): Potential for systemic absorption leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, and hyperglycemia/glucosuria. Ocular effects like cataracts or glaucoma are also documented risks, particularly with extended use or application near the eyes.

Population- and Dose-related safety

  • Population-specific safety considerations: Pediatric patients are at greater risk for systemic toxicity due to a higher ratio of skin surface area to body weight. Use in this population may require heightened monitoring for HPA axis suppression and Cushing's syndrome.
  • Dose- or exposure-related patterns: The risk of HPA axis suppression and systemic adverse effects increases with higher doses, application to large surface areas, prolonged use, and the use of occlusive dressings or when applied to skin folds.

Safety-related restrictions or limitations

  • Contraindications: Maxiflor is contraindicated in patients with a history of hypersensitivity to the active ingredient (diflorasone diacetate) or any components of the formulation. It is also restricted for use in the treatment of certain viral, fungal, or primary bacterial infections.
  • Context-of-use safety notes (as defined in official documents): Treatment should be discontinued if local irritation or signs of infection develop. Use near the eyes should be avoided to mitigate ocular risks.
  • Regulatory frequency framework used: The adverse reaction frequencies are often based on ICH E2A/E2D classifications (e.g., Common, Uncommon), which are standards used by authorities like the FDA and EMA.

Regulatory safety summary

  • The most common adverse reactions reported involve the treated skin area, including burning, itching, irritation, and dryness.
  • Prolonged or high-exposure use carries the regulatory warning of potential HPA axis suppression, a serious systemic effect.
  • Safety restrictions strictly limit the duration of use and prohibit application with occlusive materials to minimize systemic absorption.

Connection to the overall safety profile (2–4 sentences): The official safety profile for Maxiflor structures the understanding of risks by separating common local side effects from the rare, but clinically significant, systemic toxicities associated with high-potency corticosteroids. Regulatory guidance mandates a specific focus on the potential for HPA axis suppression, particularly in vulnerable populations and with extended use. This highlights that the primary safety concern is linked directly to the extent of systemic drug exposure through the skin, leading to explicit restrictions on application method and duration.

Overdose and Emergency Response

Maxiflor Overdose and when to seek help

Maxiflor is a brand name for diflorasone topical, a potent corticosteroid used for skin conditions. Overdose from topical corticosteroids is rare when the medicine is used as prescribed, but the risk increases with prolonged use, application over large areas of the body, or application to damaged skin. Since the product is applied to the skin, overdose most often occurs from systemic absorption of the drug into the body.

Signs and Symptoms of Systemic Over-Absorption

High-level or prolonged exposure to corticosteroids through the skin can lead to systemic effects. While not immediate signs of acute overdose, these manifestations indicate over-absorption and require medical evaluation:

  • Adrenal Gland Suppression: This may cause symptoms like unusual tiredness, weakness, nausea, and vomiting, due to the body's decreased ability to produce stress hormones.
  • Cushing’s Syndrome: Prolonged over-absorption can lead to symptoms such as weight gain, a rounded face, thinning skin, and high blood sugar.
  • Vision Changes: Increased pressure within the eye, potentially leading to cataracts or glaucoma, is a long-term risk associated with over-absorption.

When Immediate Medical Help is Required

If you or someone else has swallowed Maxiflor or applied significantly more than the prescribed amount, or if you suspect signs of systemic over-absorption, seek emergency medical assistance immediately.

  • Emergency Contact: Call 911 (or your local emergency number) or contact a certified Poison Control center right away.
  • Necessary Information: Have the person’s age, weight, the product name (Maxiflor), the amount used or swallowed, and the time of the exposure ready for the emergency responder.
Emergency Action Contact
Swallowing or Acute Misuse Call 911 or Poison Control immediately.
Signs of Systemic Over-Absorption Contact a healthcare provider for urgent assessment.

Therapeutic Uses of Maxiflor

What Maxiflor Treats: Main Uses and Benefits

Maxiflor is commonly used across domains where additional symptomatic support for severe skin inflammation is needed. Highly potent topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Targeting Severe Inflammatory Skin Conditions

Maxiflor is applied in clinical settings that involve acute or unstable symptom patterns, which may include conditions like resistant plaque psoriasis, severe atopic dermatitis (eczema), and inflammatory lesions such as Lichen planus. This highly potent topical treatment is primarily used across conditions characterized by periods of heightened symptoms, where the goal is to support symptomatic relief. Maxiflor may assist with supporting functional stability when symptoms related to inflammatory states become more disruptive during flare-ups.

Relieving Intense Symptom Clusters

A relevant use is for addressing severe symptoms that interfere with daily comfort and create noticeable physiological strain. It is commonly used when short-term symptomatic assistance is needed for symptom clusters involving severe pruritus (itching), pronounced redness, and swelling. It contributes to improved comfort during symptomatic periods by easing the overall symptom load.


Quick Fact: Relief for Inflammation and Pruritus

Target Domain Common Conditions Symptomatic Benefit
Recurrent Manifestations Severe Eczema, Resistant Psoriasis Supports functional stability
Symptom Cluster Intense itching (Pruritus), Redness Helps ease the overall symptom burden
Clinical Context Thickened/Chronic lesions (Hyperkeratosis) Assists with maintaining comfort

Regulatory References

  1. National Institutes of Health (NIH) DailyMed service

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Maxiflor's eligibility profile is defined by official regulatory documents based on absolute prohibitions, restrictions, and lack of established data in specific populations.

Contraindicated and Prohibited Use

  • The medicine is contraindicated in any patient with a history of hypersensitivity to its components.
  • Use is prohibited for the treatment of rosacea and perioral dermatitis.
  • Application is not recommended on sensitive anatomical areas, including the face, groin, or axillae (underarms).

Restricted Populations and Conditional Use

  • Pediatric Patients: The safety and effectiveness have not been established in this population, which is therefore restricted from use.
  • Pregnancy and Lactation: Use during pregnancy (Category C) is conditional, permissible only if the potential benefit justifies the potential risk to the fetus. Caution is required for nursing mothers.
  • Comorbid Conditions: Patients with pre-existing conditions such as Cushing's syndrome, Glaucoma, or Diabetes require special consideration due to the risk of systemic absorption effects.
  • Infections: The medicine must be discontinued if a concomitant skin infection is present and not adequately controlled.

What should I know about interactions with other medicines?

Official Interaction Profile for Maxiflor (Diflorasone Diacetate)

Interactions with Maxiflor are classified based on the potential for systemic absorption of the topical corticosteroid, which introduces pharmacokinetic and pharmacodynamic effects common to the glucocorticoid class. All documented interaction information is based on official government regulatory sources.

Interaction Type Interacting Agent Category Official Regulatory Statement
Pharmacodynamic Antidiabetic Agents Co-administration may increase the risk of hyperglycemia due to the intrinsic activity of the glucocorticoid.
Pharmacodynamic Thiazide Diuretics Co-administration may increase the risk of hypokalemia (low potassium) and other electrolyte imbalances.
Pharmacodynamic Immunosuppressants Co-administration may increase the overall severity of immunosuppression.
Pharmacokinetic Fosphenytoin, Isoniazid Co-administration may decrease the serum concentration of diflorasone (via Fosphenytoin) or decrease the serum concentration of Isoniazid.

Interaction-Related Constraints

  • Procedural Restriction: Use of occlusive dressings or wrapping the treated area is documented to substantially increase the systemic absorption of the medicine, which raises the potential for systemic, drug-related interactions.
  • Population Note: Pediatric patients may absorb proportionally larger amounts of the corticosteroid and are cited as more susceptible to systemic effects from increased exposure.
  • Contraindication: Co-use is formally prohibited in patients with a history of hypersensitivity to any component of the preparation.

Food, Alcohol, and Timing Requirements

Regulatory documentation states that there are no known interactions with food, alcohol, or specific herbal products. No explicit timing separation rules between Maxiflor and other oral medications are documented in the prescribing information.

Mechanism of Action

Maxiflor, which contains diflorasone diacetate, is a synthetic fluorinated topical corticosteroid that modulates cellular processes in the skin. The molecule enters target cells and binds to the intracellular glucocorticoid receptor (GR) in the cytoplasm, forming a ligand-receptor complex.

This complex translocates into the cell nucleus, where it acts as a transcription factor to modify the expression of specific target genes. Specifically, the activated GR complex upregulates the synthesis of lipocortins (also known as annexin A1). Lipocortins act as inhibitory proteins for the enzyme phospholipase A2.

By antagonizing phospholipase A2, Maxiflor indirectly suppresses the release of arachidonic acid from membrane phospholipids. This decrease in arachidonic acid availability diminishes the subsequent biosynthesis and release of downstream eicosanoid mediators, including prostaglandins and leukotrienes.

This molecular cascade leads to the systemic physiological modulation of the dermal microenvironment, resulting in vasoconstriction, decreased capillary permeability, and reduced leukocyte and macrophage migration and activity at the application site. The overall consequence is a local restriction of the cellular and biochemical components of the inflammatory process.

Dosage and Administration Information

The administration of Maxiflor (Diflorasone diacetate) is guided by the product labeling, detailing the appropriate application method and frequency. This medication is intended exclusively for topical application to the affected skin area and is strictly for external use only.

Official Administration Guidelines

Usage Principle Application Guidelines
Route and Application The preparation, either the 0.05% cream or the 0.05% ointment, is applied as a thin film to the treatment site.
Frequency Pattern The cream formulation is generally applied twice daily (e.g., in the morning and evening). The ointment formulation is typically applied one to three times daily, based on the standard regimen.
Duration Principle Application should be discontinued when control of the condition is achieved, rather than being used indefinitely.

Procedural Constraints and Contextual Use

Product instructions emphasize certain procedural constraints directly tied to proper administration. Contact with the eyes must be avoided during application. Furthermore, the treated area should not be bandaged or otherwise covered (occluded) unless explicitly directed, as covering the area can increase systemic absorption.

For pediatric use, administration is guided by the principle of minimizing total exposure. The use should be limited to the least amount compatible with an effective regimen. Additionally, in infants, the medication should not be used in the diaper area if tight-fitting diapers or plastic pants will be worn, as these are considered occlusive coverings.

These guidelines establish a protocol for Maxiflor's use, ensuring that its application method, dose frequency, and duration limits are followed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Maxiflor

Evidence for Use in Plaque Psoriasis

Research examining Diflorasone diacetate (the active ingredient in Maxiflor) includes studies on plaque psoriasis and primarily relies on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and often compared the topical formulation against other potent prescription topical corticosteroids or an inactive cream base. Research examined how patients with moderate-to-severe disease were observed. Outcomes linked to inflammatory or irritative states were studied, including measurements of redness (erythema), scaling, and skin thickening (induration). Studies monitored how signs like erythema, induration, and scaling evolved and findings describe patterns observed in the overall clinical assessments performed by investigators over short, defined time intervals.

Evidence for Use in Eczema (Atopic Dermatitis) and Related Conditions

Diflorasone diacetate was evaluated in studies focusing on atopic dermatitis (eczema) and related dermatoses. These trials explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. Study outcomes examined how patients reported their perceived discomfort, including measurements of intense itching (pruritus) and pronounced redness. Studies report how symptoms evolved in the observed populations during the short treatment windows, which typically lasted two to three weeks.

Understanding the Strength and Gaps in Evidence

The research base consists primarily of Randomized Controlled Trials (RCTs), a study design that provides robust data for regulatory assessment. This high evidence level refers to the consistency and design of the studies (e.g., RCTs), but the research does not determine whether an individual will have a similar outcome.

The key research limitation frames include the short duration of the core studies and the modest sample sizes used in some of the product-specific research. Furthermore, there is limited information for long-term outcomes, meaning long-term effects are not fully established regarding how symptoms evolved over an extended time and long-term patterns related to disease activity. Research provides context on what has been observed so far but does not determine whether an individual will respond similarly.

Key Studies & References Label: DIFLORASONE DIACETATE cream - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Maxiflor (FAQ)

Q: How quickly should I expect to see an improvement after starting Maxiflor?

Studies and official information indicate that clinical trials for Maxiflor commonly examine symptom changes over short, defined time intervals, often lasting between two to six weeks. Individual response time can vary based on the treated condition. Treatment with this medication is typically intended to be discontinued as soon as control of the skin condition is achieved.


Q: Are there any common Maxiflor mistakes people make when applying it?

Regulatory guidance emphasizes applying the medicine only as a thin film and strictly for external use. It is important to avoid getting Maxiflor in the eyes. Additionally, the treated skin should not be covered with bandages or occlusive dressings unless a healthcare professional has explicitly directed this, as covering the area can increase absorption.


Q: Can Maxiflor be used on the face or sensitive skin areas?

Official product information explicitly states that application is not recommended for sensitive anatomical areas, including the face, groin, or underarms (axillae). This restriction is in place due to the high potency of the medication and the potential for increased absorption and local side effects in these sensitive areas.


Q: Is it normal to feel a slight burning sensation the first time I use Maxiflor?

Burning, stinging, itching, or irritation are among the most commonly reported local adverse reactions when Maxiflor is first applied. If these effects persist, worsen significantly, or do not go away, it is important to consult a healthcare professional.


Q: What happens if I accidentally swallow a tiny amount of Maxiflor?

Maxiflor is strictly for external use only and should not be ingested. If any amount is accidentally swallowed, official guidance advises that it is recommended to contact a doctor or local poison control center immediately.


Q: Can I use Maxiflor if I have a known allergy to other steroid medications?

It is important for patients to discuss any known allergies to other topical or systemic steroids with their healthcare professional. Regulatory guidance emphasizes full disclosure of all medication allergies to the prescriber before starting treatment with Maxiflor.


Q: What are the common signs of an allergic reaction to Maxiflor?

Serious allergic reactions are rare. Symptoms that may indicate a severe reaction include rash, hives, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing. Common local reactions like temporary burning or itching are not typically categorized as a severe allergy.


Q: Are headaches a known side effect of Maxiflor?

Headache is one of the symptoms that has been reported, although infrequently, in individuals using Maxiflor. Regulatory documents note that systemic effects, such as HPA axis suppression, are a rare risk with high-potency topical steroids, and headache may be one symptom associated with systemic absorption.


Q: What should I do if I forget to apply a dose of Maxiflor?

Regulatory guidance for missed doses advises patients on how to proceed, typically suggesting that the application be made as soon as possible unless it is nearly time for the next dose. However, patients should refer to the full prescribing information or consult a healthcare professional for specific instructions on managing a missed dose.


Q: Can I use Maxiflor if I'm taking oral medications for high blood pressure?

The official interaction profile documents a risk when Maxiflor is co-administered with certain types of blood pressure medications, specifically Thiazide diuretics. This combination may increase the risk of hypokalemia (low potassium) and other electrolyte imbalances. Discussion of all oral medications with a prescriber is necessary to understand potential risks.


Q: Why is Maxiflor not recommended for children under a certain age?

The safety and effectiveness of Maxiflor have not been fully established in pediatric patients. Official safety information states that children may absorb proportionally larger amounts of the corticosteroid due to their higher skin surface area to body weight ratio, making them more susceptible to systemic effects.


Q: What are the signs that Maxiflor might not be working for my condition?

Official guidance states that treatment should be discontinued if the condition is not controlled or if local irritation or signs of infection develop. Signs that the medication may not be working include a lack of expected improvement in symptoms or if the symptoms (like redness and swelling) appear to worsen.


Q: Does Maxiflor need to be stored in the refrigerator?

No, Maxiflor should not be stored in the refrigerator or allowed to freeze. Official instructions mandate that the medicine should be stored at controlled room temperature, typically between 20 C and 25 C, and protected from excess heat, moisture, and direct light.


Q: Is there a generic version of Maxiflor available?

Yes, Maxiflor contains the active ingredient diflorasone diacetate. This active ingredient is available in generic topical cream and ointment formulations, as confirmed by regulatory product listings.


Q: Can Maxiflor be used on broken skin or open wounds?

Official safety information recommends against using this medicine on skin areas that have cuts, scrapes, or burns, or if there is an infection or sore in the area to be treated. Using it on broken skin can increase the risk of systemic absorption and associated side effects.


Q: Is it possible to develop an allergy to Maxiflor after using it for a while?

Any new signs of local adverse reactions, such as increased irritation or redness, should be discussed with a physician. While the initial contraindication relates to a pre-existing hypersensitivity, changes in the skin response can potentially develop over the course of treatment.


Q: What is the typical duration of treatment with Maxiflor?

The guiding principle for treatment is to discontinue use when control of the condition is achieved. Regulatory guidance advises limiting continuous use to the least amount of time necessary, with some documentation suggesting treatment should be limited to short periods, such as two consecutive weeks.


Q: Do food or beverages affect the way Maxiflor works?

Official regulatory documentation states that there are no known interactions between Maxiflor (when applied topically) and food, alcohol, or specific herbal products.


Q: Can men and women use Maxiflor for the same conditions?

Yes, the official indications for Maxiflor apply equally to adult men and women. It is prescribed for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in both sexes.


Q: Is Maxiflor used for conditions other than skin problems?

The medication is officially indicated as a topical dermatological product. Its use is limited to the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, meaning it is intended only for skin conditions.


Q: Does Maxiflor cause any discoloration or change in skin pigmentation?

Regulatory data indicates that change in skin color, including either lightening (hypopigmentation) or darkening (hyperpigmentation) of the treated area, is one of the reported side effects associated with high-potency topical corticosteroids.


Q: How is the potency of Maxiflor determined?

The high potency of Maxiflor is determined by regulatory bodies primarily using the vasoconstrictor assay test. This test is a standard pharmacological method that measures the ability of a topical corticosteroid to constrict blood vessels in the skin, which correlates to its anti-inflammatory power.


Q: What should be avoided immediately after applying Maxiflor?

Immediately after applying Maxiflor, care must be taken to avoid getting the medicine in the eyes, mouth, or nose. Thorough hand washing is also required after application unless the hands themselves are the area being treated.


Q: Can Maxiflor make the skin more prone to fungal infections?

Corticosteroids, due to their action, may potentially lower the body's local ability to fight infections. Official warnings advise that if a skin infection is present or develops, the use of an appropriate antifungal or antibacterial agent is required to manage the infection.

How should Maxiflor be stored and disposed of?

Official Storage and Disposal Instructions

Maxiflor (diflorasone topical) must be stored and disposed of according to strict regulatory guidelines to maintain its quality and prevent accidental harm.

Storage Component Official Requirement
Temperature Store at room temperature (20°C to 25°C).
Environmental Control Protect from freezing, excess heat, moisture, and direct light.
Packaging Keep the medicine in its original container and ensure it is tightly closed.
Access Keep out of the reach of children.
Expired/Unused Product Do not keep outdated medicine or medicine no longer needed.

Regulatory documents specify that any unused or expired Maxiflor must be disposed of safely. The official instruction is to ask your healthcare professional (a doctor or pharmacist) how to properly dispose of the medicine you do not use. This action aligns with the standard procedure for pharmaceutical waste disposal, which prioritizes drug take-back options over household trash or flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxiflor found in:

A-Z Index: